10:00 AM EDT, 06/04/2024 (MT Newswires) -- AbbVie ( ABBV ) said Tuesday that Rinvoq is now available in the US to treat pediatric patients aged two years and older with active polyarticular juvenile idiopathic arthritis and psoriatic arthritis who have not had an adequate response to or tolerance for at least one tumor necrosis factor blocker.

A new weight-based oral solution Rinvoq LQ is also available for these pediatric patients, the company said.

Price: 161.43, Change: +1.24, Percent Change: +0.77